Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
39
PMN Quote, Financials, Valuation and Earnings
Last price:
$14.99
Seasonality move
:
4.68%
Day range:
$14.09 - $15.05
52-week range:
$6.27 - $39.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.42x
Volume:
22.5K
Avg. volume:
303.2K
1-year change:
-35.07%
Market cap:
$31.4M
Revenue:
--
EPS (TTM):
-$13.58
Analysts' Opinion
-
Consensus RatingProMIS Neurosciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $64.52, ProMIS Neurosciences, Inc. has an estimated upside of 341.6% from its current price of $14.61.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $34.10 representing 100% downside risk from its current price of $14.61.
Fair Value
-
According to the consensus of 2 analysts, ProMIS Neurosciences, Inc. has 341.6% upside to fair value with a price target of $64.52 per share.
PMN vs. S&P 500
-
Over the past 5 trading days, ProMIS Neurosciences, Inc. has underperformed the S&P 500 by -6.77% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ProMIS Neurosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ProMIS Neurosciences, Inc. revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter ProMIS Neurosciences, Inc. reported revenues of --.
Earnings Growth
-
ProMIS Neurosciences, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter ProMIS Neurosciences, Inc. reported earnings per share of -$5.93.
Enterprise value:
16M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
1.40x
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.59x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
1.40x
Gross Profit (TTM):
--
Return On Assets:
-166.31%
Net Income Margin (TTM):
--
Return On Equity:
-348.3%
Return On Invested Capital:
-348.3%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$4.7K | -$18K | -- | -- | -- | |
| Operating Income | -$18.9M | -$14.7M | -$35.4M | -$4.4M | -$11.8M | |
| EBITDA | -$18.9M | -$14.7M | -$35.4M | -$4.4M | -$11.8M | |
| Diluted EPS | -$1.95 | -$0.20 | -$13.58 | $0.31 | -$5.93 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $23M | $4.9M | $17.9M | $24.5M | $21.5M | |
| Total Assets | $23.1M | $5.4M | $17.9M | $24.5M | $21.5M | |
| Current Liabilities | $1.7M | $3.1M | $9.9M | $2.6M | $12.2M | |
| Total Liabilities | $15.5M | $4.7M | $11.1M | $17.2M | $12.3M | |
| Total Equity | $7.6M | $729.8K | $6.8M | $7.3M | $9.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$11.2M | -$22M | -$27.4M | -$6.7M | -$10.2M | |
| Cash From Investing | $100 | -$1.3K | -$700 | -- | -- | |
| Cash From Financing | $24.6M | $26.6M | $21.3M | $27.1M | $21.3M | |
| Free Cash Flow | -$11.2M | -$22M | -$27.4M | -$6.7M | -$10.2M | |
PMN
Sector
Market Cap
$31.4M
$23.4M
Price % of 52-Week High
36.76%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-93.02%
-1.64%
1-Year Price Total Return
-35.07%
-21.81%
Beta (5-Year)
-0.074
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$14.17
200-day SMA
Buy
Level
$11.89
Bollinger Bands (100)
Buy
Level
7.91 - 12.13
Chaikin Money Flow
Sell
Level
-4.9M
20-day SMA
Buy
Level
$11.54
Relative Strength Index (RSI14)
Buy
Level
67.26
ADX Line
Buy
Level
33.09
Williams %R
Neutral
Level
-48.1175
50-day SMA
Buy
Level
$9.44
MACD (12, 26)
Buy
Level
3.89
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
7.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.9192)
Sell
CA Score
(Annual)
Level (-4.5686)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Buy
Ohlson Score
Level (-6.7197)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.
Stock Forecast FAQ
In the current month, PMN has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PMN average analyst price target in the past 3 months is $64.52.
-
Where Will ProMIS Neurosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that ProMIS Neurosciences, Inc. share price will rise to $64.52 per share over the next 12 months.
-
What Do Analysts Say About ProMIS Neurosciences, Inc.?
Analysts are divided on their view about ProMIS Neurosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ProMIS Neurosciences, Inc. is a Sell and believe this share price will drop from its current level to $34.10.
-
What Is ProMIS Neurosciences, Inc.'s Price Target?
The price target for ProMIS Neurosciences, Inc. over the next 1-year time period is forecast to be $64.52 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PMN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ProMIS Neurosciences, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PMN?
You can purchase shares of ProMIS Neurosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ProMIS Neurosciences, Inc. shares.
-
What Is The ProMIS Neurosciences, Inc. Share Price Today?
ProMIS Neurosciences, Inc. was last trading at $14.99 per share. This represents the most recent stock quote for ProMIS Neurosciences, Inc.. Yesterday, ProMIS Neurosciences, Inc. closed at $14.61 per share.
-
How To Buy ProMIS Neurosciences, Inc. Stock Online?
In order to purchase ProMIS Neurosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PMN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PMN
Sector
P/E ratio
--
23.34x
PEG ratio
0.00x
-0.01x
P/B ratio
3.42x
1.72x
Price / LTM sales
--
1.51x
Growth Metrics
PMN
Sector
Revenue growth
--
3.21%
Earnings growth
-2021.62%
10.12%
Revenue (5-year growth)
-100%
6.27%
Earnings forecast
--
-$0.19
Profitability
PMN
Sector
Profitability FY 2024
--
$2.7M
Return on invested capital
-348.3%
-33.62%
Return on assets
-166.31%
-29.68%
Return on equity
-348.3%
-38.89%
Earnings Date
Last Earnings Date
Aug
7
Next Earnings Date
Feb
13
Estimated Next Earnings Date
May
15
Balance Sheet
PMN
Sector
Total cash
$15.4M
$25M
Short term investments
$33.1K
$23.9M
Total assets
$18.9M
$72.8M
Long term debt
--
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
